13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001674712
Total reported value
$1.1B
$1.1B
42 檔
55.1%
The Q2 2025 SEC filing reveals that Vivo Capital, LLC held a total portfolio value of $1.1B, covering 42 public equity positions.
In Q2 2025, Vivo Capital, LLC displayed an active expansion posture, initiating 7 new positions and adding to 5 existing holdings, outstripping position reductions.
In terms of portfolio concentration, the top 5 core holdings (including SLNOEUR, VRNA, CDTX) accounted for 55.1% of total reported equity market value during Q2 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 33.94% | -0.82% | EXIT | |
| 2 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 13.49% | — | -3.15% | |
| 3 | CDTX | Cidara Therapeutics Inc | Stock-Other | 6.54% | — | +91.65% | |
| 4 | GERN | Geron CORP | Stock-Other | 3.93% | -0.06% | — | |
| 5 | SVA | Sinovac Biotech Ltd. | Stock-Other | 3.91% | +0.32% | — | |
| 6 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 3.25% | -0.12% | +50.28% | |
| 7 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 2.63% | -5.85% | EXIT | |
| 8 | TRVI | Trevi Therapeutics Inc | Stock-Other | 2.51% | +3.63% | +28.67% | |
| 9 | ✓ | Avadel Pharmaceuticals PLC ADR | Stock-Other | 2.43% | — | — | |
| 10 | AKRO | Akero Therapeutics Inc | Stock-Other | 2.37% | — | +116.08% | |
| 11 | CMPX | Compass Therapeutics Inc | Stock-Other | 1.61% | -2.65% | +69.95% | |
| 12 | VRDN | Viridian Therapeutics Inc | Stock-Other | 1.41% | -0.27% | EXIT | |
| 13 | CTMX | Cytomx Therapeutics Inc | Stock-Other | 1.34% | — | — | |
| 14 | ACRS | Aclaris Therapeutics Inc | Stock-Other | 1.29% | +1.15% | — | |
| 15 | ZBIO | Zenas Biopharma Inc | Stock-Other | 1.17% | — | — | |
| 16 | DYN | Dyne Therapeutics Inc | Stock-Other | 1.09% | +0.81% | — | |
| 17 | ABEO | Abeona Therapeutics Inc | Stock-Other | 1.07% | — | — | |
| 18 | DBVT | Dbv Technologies Sa-spon Adr | Stock-Other | 0.99% | -1.87% | — | |
| 19 | TRML | Tourmaline Bio Inc | Stock-Other | 0.97% | — | — | |
| 20 | RZLT | Rezolute Inc | Stock-Other | 0.96% | — | — | |
| 21 | CMPS | Compass Pathways PLC | Stock-Other | 0.96% | -0.09% | EXIT | |
| 22 | CRVS | Corvus Pharmaceuticals Inc | Stock-Other | 0.91% | +0.42% | — | |
| 23 | ERAS | Erasca Inc | Stock-Other | 0.88% | -9.44% | — | |
| 24 | IOBTQ | Io Biotech Inc | Stock-Other | 0.88% | — | — | |
| 25 | CATBUSD | Astria Therapeutics Inc | Stock-Other | 0.85% | — | — | |
| 26 | CELC | Celcuity Inc | Stock-Other | 0.83% | — | — | |
| 27 | COGT | Cogent Biosciences Inc | Stock-Other | 0.82% | -1.35% | EXIT | |
| 28 | DCTH | Delcath Systems Inc | Stock-Other | 0.79% | — | -24.08% | |
| 29 | PRAX | Praxis Precision Medicines I | Stock-Other | 0.72% | -0.79% | — | |
| 30 | DRUG | Bright Minds Biosciences Inc | Stock-Other | 0.67% | +0.19% | — | |
| 31 | OLMA | Olema Pharmaceuticals Inc | Stock-Other | 0.66% | -0.06% | — | |
| 32 | SLN | Silence Therapeutics Plc-adr | Stock-Other | 0.66% | — | — | |
| 33 | VSTM | Verastem Inc | Stock-Other | 0.65% | — | — | |
| 34 | TIL | Instil Bio Inc | Stock-Other | 0.62% | +0.01% | -50.00% | |
| 35 | UNCY | Unicycive Therapeutics Inc | Stock-Other | 0.56% | -0.74% | — | |
| 36 | SERA | Sera Prognostics Inc-a | Stock-Other | 0.47% | -0.01% | — | |
| 37 | ETNBGBP | 89bio Inc | Stock-Other | 0.38% | — | — | |
| 38 | TNGX | Tango Therapeutics Inc | Stock-Other | 0.31% | +0.19% | — | |
| 39 | SRZN | Surrozen Inc | Stock-Other | 0.24% | -0.01% | — | |
| 40 | TENX | Tenax Therapeutics Inc | Stock-Other | 0.12% | +3.04% | — | |
| 41 | BOLT | Bolt Biotherapeutics Inc | Stock-Other | 0.10% | +0.01% | — | |
| 42 | DTIL | Precision Biosciences Inc | Stock-Other | — | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | CDTX | Cidara Therapeutics Inc | +4.6% | +91.65% | Add |
| 2 | SVA | Sinovac Biotech Ltd. | +3.9% | NEW | New buy |
| 3 | ORIC | Oric Pharmaceuticals Inc | +1.7% | +50.28% | Add |
| 4 | VRNA | Verona Pharma PLC - Adr | +1.4% | -3.15% | Trim |
| 5 | CTMX | Cytomx Therapeutics Inc | +1.3% | NEW | New buy |
| 6 | AKRO | Akero Therapeutics Inc | +1.3% | +116.08% | Add |
| 7 | DBVT | Dbv Technologies Sa-spon Adr | +1% | NEW | New buy |
| 8 | CMPX | Compass Therapeutics Inc | +0.7% | +69.95% | Add |
| 9 | PRAX | Praxis Precision Medicines I | +0.7% | NEW | New buy |
| 10 | UNCY | Unicycive Therapeutics Inc | +0.6% | NEW | New buy |
| 11 | TNGX | Tango Therapeutics Inc | +0.3% | NEW | New buy |
| 12 | SLN | Silence Therapeutics Plc-adr | +0.3% | — | Unchanged |
| 13 | RZLT | Rezolute Inc | +0.2% | — | Unchanged |
| 14 | 430 | Terns Pharmaceuticals Inc | +0.1% | — | Unchanged |
| 15 | BOLT | Bolt Biotherapeutics Inc | +0.1% | NEW | New buy |
| 16 | ETNBGBP | 89bio Inc | 0% | — | Unchanged |
| 17 | CELC | Celcuity Inc | 0% | — | Unchanged |
| 18 | DTIL | Precision Biosciences Inc | — | — | Unchanged |
| 19 | IOBTQ | Io Biotech Inc | 0% | — | Unchanged |
| 20 | ALGS | Aligos Therapeutics Inc | 0% | EXIT | Sold out |
| 21 | ALLKGUSD | Allakos Inc | 0% | EXIT | Sold out |
| 22 | CRVS | Corvus Pharmaceuticals Inc | 0% | — | Unchanged |
| 23 | TENX | Tenax Therapeutics Inc | -0.1% | — | Unchanged |
| 24 | ZBIO | Zenas Biopharma Inc | -0.1% | — | Unchanged |
| 25 | COGT | Cogent Biosciences Inc | -0.1% | — | Unchanged |
| 26 | ABEO | Abeona Therapeutics Inc | -0.1% | — | Unchanged |
| 27 | OLMA | Olema Pharmaceuticals Inc | -0.1% | — | Unchanged |
| 28 | SRZN | Surrozen Inc | -0.2% | — | Unchanged |
| 29 | BOLT1EUR | Bolt Biotherapeutics Inc | -0.2% | EXIT | Sold out |
| 30 | TRML | Tourmaline Bio Inc | -0.2% | — | Unchanged |
| 31 | CATBUSD | Astria Therapeutics Inc | -0.3% | — | Unchanged |
| 32 | CMPS | Compass Pathways PLC | -0.3% | — | Unchanged |
| 33 | SERA | Sera Prognostics Inc-a | -0.3% | — | Unchanged |
| 34 | VRDN | Viridian Therapeutics Inc | -0.3% | — | Unchanged |
| 35 | ✓ | Avadel Pharmaceuticals PLC ADR | -0.4% | — | Unchanged |
| 36 | ERAS | Erasca Inc | -0.4% | — | Unchanged |
| 37 | TRVI | Trevi Therapeutics Inc | -0.4% | +28.67% | Add |
| 38 | DYN | Dyne Therapeutics Inc | -0.5% | — | Unchanged |
| 39 | DCTH | Delcath Systems Inc | -0.5% | -24.08% | Trim |
| 40 | ACRS | Aclaris Therapeutics Inc | -0.5% | — | Unchanged |
| 41 | DRUG | Bright Minds Biosciences Inc | -0.5% | — | Unchanged |
| 42 | VSTM | Verastem Inc | -0.6% | — | Unchanged |
| 43 | RGLS | Regulus Therapeutics Inc | -0.6% | EXIT | Sold out |
| 44 | TIL | Instil Bio Inc | -0.7% | -50.00% | Trim |
| 45 | ✓ | -0.9% | EXIT | Sold out | |
| 46 | GERN | Geron CORP | -1.8% | — | Unchanged |
| 47 | SLNOEUR | Soleno Therapeutics Inc | -8.3% | -11.22% | Trim |
According to official SEC Form 13F filings, Vivo Capital, LLC reported a total U.S. public equity portfolio value of $1.1B across 42 disclosed positions in Q2 2025.
During Q2 2025, Vivo Capital, LLC's top holdings by market value included SLNOEUR (33.9%)、VRNA (13.5%)、CDTX (6.5%). The largest single position, SLNOEUR, represented 33.9% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
SVA
市值: $38.2M
Top Position Liquidated / Trimmed
前期市值: $6.5M
In Q2 2025, Vivo Capital, LLC made 21 total portfolio adjustments, initiating 7 new buys, adding to 5 positions, trimming 4 holdings, and fully liquidating 5 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.